Omadacycline for the treatment of skin and soft tissue infections

Antonio Vena; Nadia Castaldo; Daniele Roberto Giacobbe; Alberto Fantin; Matteo Bassetti

doi:10.1097/QCO.0000000000001089

Omadacycline for the treatment of skin and soft tissue infections

Curr Opin Infect Dis. 2024 Dec 24. doi: 10.1097/QCO.0000000000001089. Online ahead of print.

Authors

Antonio Vena^{1

2}, Nadia Castaldo³, Daniele Roberto Giacobbe^{1

2}, Alberto Fantin^{3

4}, Matteo Bassetti^{1

2}

Affiliations

¹ Department of Health Sciences (DISSAL), University of Genoa.
² Clinica Malattie Infettive, IRCCS San Martino Polyclinic Hospital, Genoa.
³ Department of Pulmonology, University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
⁴ Respiratory Medicine Unit, Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

PMID: 39786987
DOI: 10.1097/QCO.0000000000001089

Abstract

Purpose of review: To evaluate the current evidence on the use of omadacycline for the treatment of skin and soft tissue infections (SSTIs).

Recent findings: This narrative review examines the available data on the pharmacology, clinical efficacy, safety profile, and comparative effectiveness of omadacycline in treating SSTIs, with a focus on its potential role in everyday clinical practice.

Summary: Omadacycline is a viable option for outpatient therapy and early discharge in patients with SSTIs, particularly in frail populations and those undergoing chronic polypharmacotherapy. Emerging real-world evidence highlights its potential utility beyond approved indications, particularly for infections caused by multidrug-resistant microorganisms where treatment options are limited. However, further studies are needed to confirm its role in contexts beyond its current approvals.